Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.

doi:10.1007/s10147-023-02360-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.

International journal of clinical oncology - 1 Aug 2023

Mishima Saori, Naito Yoichi, Akagi Kiwamu, Hayashi Naomi, Hirasawa Akira, Hishiki Tomoro, Igarashi Ataru, Ikeda Masafumi, Kadowaki Shigenori, Kajiyama Hiroaki, Kato Motohiro, Kenmotsu Hirotsugu, Kodera Yasuhiro, Komine Keigo, Koyama Takafumi, Maeda Osamu, Miyachi Mitsuru, Nishihara Hiroshi, Nishiyama Hiroyuki, Ohga Shouichi, Okamoto Wataru, Oki Eiji, Ono Shigeru, Sanada Masashi, Sekine Ikuo, Takano Tadao, Tao Kayoko, Terashima Keita, Tsuchihara Katsuya, Yatabe Yasushi, Yoshino Takayuki, Baba Eishi

Abstract excerpt

The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy in patient with tumor mutation burden-high (TMB-H)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Biomarkers, Tumor

Share to Brain Neoplasms

Share to East Asian People

Share to Hematology

Share to Immunotherapy

Share to Japan

Share to Medical Oncology

Source

Open in PubMed Open full text

Identifiers

PMID: 37300720
DOI: 10.1007/s10147-023-02360-8
PMCID: PMC10390617

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.PMID 37300720Read ↗

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read ↗

First Tissue-Agnostic Drug Approval IssuedSemantic proximity Read ↗

Expert consensus on the detection and clinical application of tumor mutational burden.Semantic proximity Read ↗

TMBpred: A bioinformatics tool for precise prediction of the Tumor Mutation Burden in 14 cancer typesSemantic proximity Read ↗

First report: PLATFORM study for precision treatment of rare tumors in China.Semantic proximity Read ↗

Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma.Semantic proximity Read ↗

Advances in sarcoma diagnostics and treatmentSemantic proximity Read ↗

Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan.Semantic proximity Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

The Impact of TMB on Immunotherapy Protocols: A Comprehensive Analysis of Four Major CancersSemantic proximity Read ↗

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.Semantic proximity Read ↗

Special report: multiple molecular testing of cancers to identify targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.